Publication:

Safety of voriconazole in treatment of fungal infections

Immunocompromised patients are at more risk in developing fungal infections particularly with Candida and Aspergillus species being the mycoses most commonly identified. Previously, amphotericin-B is the drug of choice for the treatment of systemic infections caused by Candida and Aspergillus species. Due to its high incidence of toxicity, its use has been limited in many cases. Voriconazole is the newest triazole synthesized against fungal infections and was approved by FDA in 2002 for the treatment of invasive aspergillosis and refractory infections of Scedosporium apiospermum and Fusarium spp.